The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Pfizer PFE is set to release its fourth-quarter and full-year 2025 results on Feb. 3, with investor attention focused on ...

Multiple companies and organizations have announced early results about their COVID-19 vaccines. Here's what we know about ...

Pfizer announced on Sept. 30 it will participate in a new government direct-to-consumer drug sale website. TrumpRx, which is expected to launch at the beginning of next year, will allow patients to ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Pfizer is investing in oncology and GLP-1 drugs, among other things, to keep its growth prospects bright. Western Union is ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

Pfizer CEO Albert Bourla speaks shakes hands with U.S. President Donald Trump in a White House event on Tuesday. President Trump and Pfizer announced a deal to cut drug pricing yesterday. And it looks ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...